Urogenital Infections and Inflammations

T.E. Bjerklund Johansen, F. M.E. Wagenlehner, Y.-H. Cho, T. Matsumoto, J. N. Krieger, D. Shoskes, K. Naber

Congenital urogenital abnormalities in children

 Gitte M. Hvistendahl 1
Yazan F. Rawashdeh 2


1 Aarhus University Hospital, Aarhus, Denmark
2 Paediatric Urology Section, Department of Urology, Aarhus University Hospital, -, Denmark

Abstract

Congenital urogenital abnormalities cover a wide range of conditions, both anatomically and functionally, which may cause UTI, renal scarring and end stage renal disease. Obstructive uropathy seems to be one of the more important disorders to diagnose and follow to prevent UTI and deterioration of kidney function. However, evidence of exactly which anomalies pose the greatest risk and stand to benefit from either prophylactic precautions or surgery is still sparse. The available data for UTI and upper urinary tract obstruction suggest that continuous antibiotic prophylaxis (CAP) and possibly male circumcision reduce the incidence of pyelonephritis in infants with hydroureteronephrosis.


Summary of recommendations

  1. There is no need for CAP in infants with mild renal pelvic dilatation as the resolution rate is high and the risk of UTI low (GoR B).
  2. CAP is recommended during the first 6–12 months of life in infants with obstructive hydroureteronephrosis, especially with ureteric dilation >11 mm (GoR B).
  3. In high risk urinary tract abnormalities circumcision needs to be taken into consideration when counselling parents (GoR C).
  4. Surgery has to be undertaken whenever CAP fails or other signs of worsening of the obstruction occurs (GoR C).

1 Introduction

Over time routine prenatal ultrasound has detected an increasing number of fetal abnormalities among which the most common are of urogenital origin. Antenatal hydronephrosis (AH) is the most frequent reported congenital anomaly, occurring in 1–5% of all pregnancies [1]. Upper urinary tract dilatation may be associated with vesicoureteral reflux (VUR), obstructive uropathies, multicystic dysplastic kidney (MCDK) and congenital megaureter [2]. It is crucial to identify which of the AH will become clinically significant to prevent deterioration of renal function postnatally. If not recognized on prenatal ultrasound urinary tract anomalies may manifest later in life as pyelonephritis, hypertension or end stage renal failure.

Some studies have shown that infants with AH are at increased risk of postnatal urinary tract infection (UTI) [3] and that the risk increases with severity and persistence during the first year of life [3], [4], [5]. This underlines the importance of early diagnosis, planning of relevant follow-up as well as decision on the need for prophylactic initiatives or surgery.

There are many challenges and controversies regarding the extent of postnatal follow-up with regards to the timing and magnitude of tests needed to prevent irreversible damage of the renal parenchyma. Likewise, the need for antibiotic prophylaxis is an ongoing discussion, when it comes to deciding who, when and for how long. Another challenge is to determine if and when to operate, since many do well without surgery.

This chapter will focus on inborn urinary tract abnormalities in terms of definition, diagnosis, evaluation and management with special reference to UTI.

Inborn urogenital abnormalities are a heterogeneous group of abnormalities of the urinary tract and genitalia. The uropathy may be obstructive or non-obstructive. Obstructive uropathy is either an upper urinary tract obstruction, uretero-pelvic junction obstruction (UPJO), vesico-ureteral junction obstruction (VUJO) and primary non-refluxing obstructive megaureter (PNROM), or a lower urinary tract obstruction. Lower urinary tract obstruction may be an anatomical (posterior urethral valve, PUV) or a functional obstruction (neurogenic bladder or dysfunctional voiding). Non-obstructive uropathies are vesicoureteral reflux (VUR), MCDK and a subgroup of megaureters. Abnormalities of the genitalia are rarely obstructive and literature on the association between genital anomalies and UTI is scarce.

Vesicoureteral reflux and spina bifida are discussed separately in another section. Therefore, the main topics of this overview will focus on the upper urinary tract with special attention on hydronephrosis and obstructive uropathies.

2 Methods

A systematic literature search was performed for the last 20 years in MEDLINE and the Cochrane library with the following key words; congenital urinary tract anomalies, hydronephrosis, obstruction, megaureter, posterior urethral valve AND UTI with the following criteria: English publications, human studies, clinical trials, meta-analyses, review, randomized clinical trial, comparative study, ages birth to 16 years old.

A total of 77 publications were identified, which were screened by title and abstract. Finally, 20 publications were included into this review and supplemented by publications mentioned in the selected publications or known by the author.

The studies were rated according to the level of evidence (LoE) and the strength of recommendations graded (GoR) according to a system used in the EUA guidelines (2015) modified from the Oxford Centre for Evidence-based Medicine [6].

3 Results

Congenital obstructive abnormalities of the upper urinary tract that may cause UTI are rarely addressed in the literature with particular reference to UTI. The literature search has revealed a limited number of very heterogeneous studies with relative low level of evidence. There are no randomized studies and controlled studies are few.

3.1 Postnatal evaluation of antenatal hydronephrosis – clinical spectrum

The incidence of AH (defined as renal pelvic diameter (RPD) ≥5 mm) is 0.59–0.65% [8], [9]. Hydronephrosis does not necessarily imply obstruction nor does it say anything about the function of the affected kidney. Furthermore, there is evidence that many mild cases of AH spontaneously improve or resolve [4], [9], [10], [11].

Postnatal investigations beside physical examination and ultrasonography (US) differs to some extend between centres according to the local standards, but may include voiding cysto-urethrography (VCUG), Technitium-mercapto-acetyltriglycine scintigraphy (MAG3) and dimercaptosuccinic acid scintigraphy (DMSA).

Typically, the first postnatal US will be delayed for 1 week to avoid false negative results during the period, when the baby is oliguric. Based on the results of the first US, the severity of the hydronephrosis, bilateral abnormality and involvement of the ureters and bladder, follow-up is individualized.

Voiding cysto-urethrography is carried out, if VUR, bladder or urethral pathology are suspected. Whenever VUR is diagnosed a DMSA scan is undertaken to determine the differential function and any renal scarring.

Diuretic renograms are taken to diagnose obstructive uropathy defined as partial or no response to furosemide administration on MAG3.

Many studies have analysed outcome data on antenatally detected hydronephrosis as well as the results of the postnatal work-up, and the deviating results reflect a wide spectrum of study designs over a long period of time [2], [10], [11], [12], [13], [14]. More recent prospective studies find UPJO more common than VUR (40–45% vs. 30–33%) followed by PUV (7–13%) and vesico-ureteral junction obstruction (VUJO) (5–6%) [2], [11] (LoE 2b). Hitherto, obstructive uropathies seem to be more frequent than non-obstructive uropathies in neonatal hydronephrotic kidneys. However, another studies found hydronephrosis without other abnormalities to be the largest group identified at postnatal US [15], which may reflect different definitions of RPD and referral practices.

3.2 Risk factors for UTI with antenatal hydronephrosis

Children with AH are at increased risk of postnatal UTI [3]. Studies on the outcome of isolated AH have concluded that infants with mild renal pelvic dilatation only need clinical and ultrasound follow-up as the resolution rate is high and the risk of UTI is rather low [4], [8]. In the group of infants with normal postnatal US the incidence of UTI is 3.8% resembling that in the normal population [15], [16].

Since UTI is associated with significant morbidity and potential long-term medical problems, it seems essential to identify the infants with AH, that require special attention postnatally in terms of more investigations, closer follow-up, CAP or even surgery to reduce the risk of especially febrile UTI.

Ongoing uncertainty about the effectiveness of antibiotic prophylaxis for preventing UTI and concerns about long-term adverse effects of antibiotics have been raised, particularly related to the risk of bacterial resistance, which further emphasizes the need for consensus in this area.

The studies presenting results of the association between AH and risk factors for UTI are very heterogeneous. There are no randomized trials, some are prospective cohort studies and others are retrospective observational studies with obvious limitations due to study design. However, all resent studies show increased risk of febrile UTI with hydronephrosis, especially with high grade hydronephrosis and hydroureteronephrosis [15], [17], [18]. At the same time female gender, no antibiotic prophylaxis and uncircumcised boys often were shown to have a higher risk of catching a UTI early in life [17], [19], [20].

A Brazilian prospective study included 172 with AH, all on CAP if RPD >10 mm and/or VUR on VCUG. None were circumcised and the incidence of UTI was 14% (74% were on CAP) [17] (LoE 3). Analysis showed independent predictors of UTI to be female gender and clinically significant uropathy. Limitations of the study were uncertainty about the accurate incidence of UTI (method of urine sampling, timing of sampling, symptoms), compliance with CAP and a small number of events (UTI), which make interpretation of the results more difficult.

Lidefelt et al. conducted a small prospective study of 103 infants with AH and a postnatal follow-up, where those with RPD >15 mm and/or VUR grade III–V were kept on CAP. The number of significant uropathies in the group of abnormal postnatal US (n=50) were few, and only in infants with dilated VUR on CAP and in a single infant with megaureter, UTI was detected [15] (LoE 3). As it was a small study with a limited number of events and many hydronephrosis without other abnormalities the conclusion was not to recommend CAP in newborns with AH, who do not have nephrourological abnormalities or clinically significant VUR.

In a retrospective observational study 405 infants with AH referred to a tertiary centre for further follow-up were assigned to either a CAP group or a no CAP group and outcome on primarily febrile UTI as well as the circumcision status were noted. Independent risk factors for febrile UTI were ureteral dilatation, high-grade VUR and UVJO. More specifically, children with ureteral dilation >11 mm not maintained on CAP had a 5.54 fold increased risk of febrile UTI compared to those on CAP [19] (LoE 3). Interestingly, contrary to other studies the circumcision status did not have any impact on the risk of developing febrile UTI.

As the study group were infants referred to a tertiary center, they may represent a selected group of high risk cases not representative of the general population, which could have influenced the initial decision on circumcision and CAP status and hence the incidence of UTI.

A Canadian group published a number of studies on risk factors for febrile UTI [18], [20]. A retrospective database review of 376 infants with AH and risk factors such as high grade hydronephrosis, VUR, CAP and circumcision status showed that antibiotic prophylaxis was prescribed preferentially to females, those with high grade hydronephrosis and those with VUR [20] (LoE 3). Febrile UTI was detected in 13.3% and further analysis found high grade hydronephrosis, female gender and uncircumcised status in males to be independent risk factors for febrile UTI. Antibiotic prophylaxis was not associated to a reduced risk of febrile UTI in this study group. The relative low number of events (febrile UTI) and the uncertainty about the compliance with CAP may explain this surprising finding. So the researchers designed a prospective longitudinal study to further address those limitations [18] (LoE 2b). Data were collected on 334 patients and febrile UTI developed in 19%. Females and uncircumcised males with high grade hydroureteronephrosis had significantly higher febrile UTI rates and thus may benefit from CAP, provided that patients with VUR were excluded from the study. Despite the well-designed study, the referral practise may result in a selected group of high grade hydronephrosis, which potentially bias the results.

3.3 Obstructive hydronephrosis/hydroureteronephrosis

Several studies have repeatedly shown hydroureteronephrosis to be associated with febrile UTI [5], [19], [21], [22], [23]. Especially, the infants with moderate to severe dilatation of the ureter (>11 mm) seem to be at risk. In this group of patients CAP and male circumcision are believed to reduce the incidence of febrile UTI and thus may prevent deterioration of kidney function. Often these prophylactic initiatives serve as temporary precautions in order to postpone surgery until the child is older.

A retrospective evaluation of 105 patients with severe hydronephrosis due to obstruction and no CAP showed a high incidence of febrile UTI (36.2%), especially before the age 6 months and in infants with lower ureteral obstruction compared to those with UPJO [21] (LoE 3). More than 70% underwent corrective surgery, when UTI or any other sign of worsening of the obstruction occurred. In the group followed without surgical intervention UTI developed in 42% leading to the recommendation, that infants with severe obstructive hydronephrosis should be treated with CAP at least for 6 months. The lack of control group, possible selection bias and small numbers of lower ureteral obstruction cases call for further prospective studies.

In 2008 the same institution published a larger retrospective study of 430 patients with non-refluxing hydronephrosis. A comparison of patients with vs without obstructive uropathy confirmed the high incidence of febrile UTI (39%) in neonates with obstructive uropathy and severe hydronephrosis or hydroureteronephrosis [5] (LoE 3).

In a small group of 49 children with 56 primary obstructive megaureters who was observed conservatively, UTI was the most common complication and turned out to be 55% lower in infants on CAP. Prophylaxis appeared particularly effective in the first 6 months of life, but even during the second year of life there still was a high incidence of UTI in an untreated group (0.46 UTI/year). Only 23% were treated surgically either primarily or after a period of observation with repeated renograms. Congenital kidney hypoplasia seemed to be more related to adverse outcome than the degree of obstruction and the rate of spontaneous resolution was about 50% [22] (LoE 3). Limitations of the study were the retrospective approach, a heterogeneous group of patients (a mixture of AH and hydronephrosis incidentally detected later in life) and the relatively small number of patients. However, the authors concluded in keeping with other groups in terms of recommending CAP to infants with hydroureteronephrosis [5], [18], [19], [21].

The latest prospective study of the fate of primary non-refluxing megaureters looked into the risk factors for febril UTI, indications for surgery and time to resolution [23] (LoE 2b). Similar to related studies the incidence of febrile UTI was 34% [5], [21]. As many as 76% of megaureters resolved during follow-up and a ureteral diameter of ≥17 mm was significantly associated with a higher rate of surgical intervention. Furthermore, circumcision (numbers-needed-to-treat, NNT was 4.5) and CAP (NNT was 3) significantly decreased the rate of febrile UTI. Again, interpretation of the results may be biased by referral bias, small number of certain subgroups of patients and a relative short follow-up.

In general, spontaneous resolution rates are high in cases with obstructive megaureter, CAP is recommended since the risk of febrile UTI is increased during the first 6 to 12 months of life and surgery is postponed, although the chance of having an operation varies widely (23–73%).

3.4 Circumcision in boys with urinary tract abnormalities

The risk of UTI in a boy with an anatomically normal urinary tract is 1%. Circumcision in a normal boy will reduce the risk of UTI by 90% [24]. In most cases, circumcision in boys is carried out for cultural or religious reasons, but it is also undertaken, because it is thought to improve hygiene and reduce the risk for certain diseases as well as UTI. Since the risk of UTI is increased in boys with complex abnormalities of the urinary tract, circumcision may turn out to be beneficial in chosen conditions [18], [20], [23]. Complication rates following circumcision vary between 2 and 10% [25], which must be taken into consideration when calculating the risk/benefit ratio for a particular group of patients.

A meta-analysis of published data on the effect of circumcision on the risk of UTI in boys has shown, that the number of normal boys who need to be circumcised to prevent one UTI is 111 [26] (LoE 1b). Furthermore, the risk of recurrence of UTI in boys with recurrent UTI and high grade VUR was 10% and 30% and the NNT were 11 and 4 respectively. Considering the risk of complications of male circumcision, the net clinical benefit is concluded acceptable in boys at high risk of UTI.

Recently, a review made a risk/benefit calculation of what evidence exists for circumcision in boys with abnormalities of the urinary tract (VUR, PUJO, VUJO and PUV) [27] (LoE 2b). The risk of UTI was significant in boys with VUR, VUJO and PUV resulting in a plausible protective effect of circumcision and an estimated NNT of 4, 3 and 2 respectively (Table 1).

Other studies on risk factors for febrile UTI in hydronephrosis and hydroureteronephrosis single out uncircumcised status as an independent risk factor in cases with high grade hydroureteronephrosis [18], [20], [23].

Table 1: Tabulation of UTI risk for abnormalities of the urinary tract in boys correlated with benefit from antibiotics, possible benefit from circumcision (plausible = projection from epidemiological studies of Wiswell et al.) [27].
Condition Risk of UTI Protective effect of antibiotic prophylaxis? Protective effect of circumcision Circumcisions NNT to prevent 1 UTI
VUR 30% [26] In dilating reflux [29] Plausible Estimated 4
VUJO 40% [5] Reduction incidence 50% [21] Plausible Estimated 3
PUJO 14% [5] ? Plausible Estimated 10
PUV 56% [28] ? Retrospective case-note review [28] 2 [28]

The efficacy of circumcision in boys with PUV was documented in a retrospective cross-sectional case note review [28] (LoE 2b). Seventy-eight patients were identified and 27 were subsequently circumcised for religious reasons. The incidence of UTI was reduced by 83% after circumcision and further calculations showed, that every circumcision on average prevents 1 UTI.

Despite the lack of studies with focus on the association between male circumcision and the risk of UTI in specific urinary tract abnormalities, the existing studies on risk factors for UTI in hydronephrosis and PUV suggest that circumcision status may influence the incidence of UTI. Therefore, in high risk urinary tract abnormalities circumcision needs to be taken into consideration when counselling parents.

4 Further research

For the time being the association between UTI and obstructive uropathy is only explored to a limited extend. There is a need for detailed research on risk factors for UTI in congenital upper urinary tract obstruction with strict inclusion and exclusion criteria preferably in a randomized-controlled setting. Likewise, the benefits of CAP vs. circumcision in boys as well as the risk/benefit of an operation compared to CAP needs clarification. Long term follow-up on each modality (CAP, no CAP, surgery) will add further knowledge to the way we follow or treat the patients. Since many of the anomalies of interest are rare, a multicentre approach seems to be worth considering.

5 Conclusions

There is a wide variability in the management of upper urinary tract obstruction. Continuous antibiotic prophylaxis is typically prescribed postnatally, whenever hydronephrosis is diagnosed awaiting further diagnostic work-up, before deciding whether or not to continue the prophylaxis. Many studies have documented a high resolution rate and a low risk of UTI in mild hydronephrosis during the first year. The criteria for keeping the infant on CAP vary to some extent depending on the local cut-off levels for RPD, ureteric dilatation and VUR grade. Despite the heterogeneity of the studies, the relative low level of evidence, lack of randomized studies, small study populations and other study limitations, there seems to be a general finding of the need for CAP in infants with hydroureteronephrosis and possibly a benefit of male circumcision in the same group of patients. Whether CAP in this group of patients merely postpones surgery or maybe even precludes it, needs to be looked further into.


References

[1] Nguyen HT, Herndon CD, Cooper C, Gatti J, Kirsch A, Kokorowski P, Lee R, Perez-Brayfield M, Metcalfe P, Yerkes E, Cendron M, Campbell JB. The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis. J Pediatr Urol. 2010 Jun;6(3):212-31. DOI: 10.1016/j.jpurol.2010.02.205
[2] Gokce I, Biyikli N, Tugtepe H, Tarcan T, Alpay H. Clinical spectrum of antenatally detected urinary tract abnormalities with respect to hydronephrosis at postnatal ultrasound scan. Pediatr Surg Int. 2012 May;28(5):543-52. DOI: 10.1007/s00383-012-3072-z
[3] Walsh TJ, Hsieh S, Grady R, Mueller BA. Antenatal hydronephrosis and the risk of pyelonephritis hospitalization during the first year of life. Urology. 2007 May;69(5):970-4. DOI: 10.1016/j.urology.2007.01.062
[4] Coelho GM, Bouzada MC, Pereira AK, Figueiredo BF, Leite MR, Oliveira DS, Oliveira EA. Outcome of isolated antenatal hydronephrosis: a prospective cohort study. Pediatr Nephrol. 2007 Oct;22(10):1727-34. DOI: 10.1007/s00467-007-0539-6
[5] Lee JH, Choi HS, Kim JK, Won HS, Kim KS, Moon DH, Cho KS, Park YS. Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection. J Urol. 2008 Apr;179(4):1524-8. DOI: 10.1016/j.juro.2007.11.090
[6] European Association of Urology. Methodology section. In: European Association of Urology, editor. Guidelines Edition 2015. Arnhem: European Association of Urology; 2015. p. 3. Available from: http://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn..pdf
[7] Dudley JA, Haworth JM, McGraw ME, Frank JD, Tizard EJ. Clinical relevance and implications of antenatal hydronephrosis. Arch Dis Child Fetal Neonatal Ed. 1997 Jan;76(1):F31-4. DOI: 10.1136/fn.76.1.F31
[8] Livera LN, Brookfield DS, Egginton JA, Hawnaur JM. Antenatal ultrasonography to detect fetal renal abnormalities: a prospective screening programme. Br Med J. 1989 May 27;298(6685):1421-3.
[9] Tombesi MM, Alconcher LF. Short-term outcome of mild isolated antenatal hydronephrosis conservatively managed. J Pediatr Urol. 2012 Apr;8(2):129-33. DOI: 10.1016/j.jpurol.2011.06.009
[10] Woodward M, Frank D. Postnatal management of antenatal hydronephrosis. BJU Int. 2002 Jan;89(2):149-56. DOI: 10.1046/j.1464-4096.2001.woodward.2578.x
[11] Ahmadzadeh A, Tahmasebi M, Gharibvand MM. Causes and outcome of prenatally diagnosed hydronephrosis. Saudi J Kidney Dis Transpl. 2009 Mar;20(2):246-50.
[12] Kitagawa H, Pringle KC, Stone P, Flower J, Murakami N, Robinson R. Postnatal follow-up of hydronephrosis detected by prenatal ultrasound: the natural history. Fetal Diagn Ther. 1998 Jan-Feb;13(1):19-25. DOI: 10.1159/000020795
[13] Gunn TR, Mora JD, Pease P. Antenatal diagnosis of urinary tract abnormalities by ultrasonography after 28 weeks' gestation: incidence and outcome. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 1):479-86.
[14] Jaswon MS, Dibble L, Puri S, Davis J, Young J, Dave R, Morgan H. Prospective study of outcome in antenatally diagnosed renal pelvis dilatation. Arch Dis Child Fetal Neonatal Ed. 1999 Mar;80(2):F135-8. DOI: 10.1136/fn.80.2.F135
[15] Lidefelt KJ, Herthelius M. Antenatal hydronephrosis: infants with minor postnatal dilatation do not need prophylaxis. Pediatr Nephrol. 2008 Nov;23(11):2021-4. DOI: 10.1007/s00467-008-0893-z
[16] Hellström A, Hanson E, Hansson S, Hjälmås K, Jodal U. Association between urinary symptoms at 7 years old and previous urinary tract infection. Arch Dis Child. 1991 Feb;66(2):232-4. DOI: 10.1136/adc.66.2.232
[17] Coelho GM, Bouzada MC, Lemos GS, Pereira AK, Lima BP, Oliveira EA. Risk factors for urinary tract infection in children with prenatal renal pelvic dilatation. J Urol. 2008 Jan;179(1):284-9. DOI: 10.1016/j.juro.2007.08.159
[18] Braga LH, Farrokhyar F, D'Cruz J, Pemberton J, Lorenzo AJ. Risk factors for febrile urinary tract infection in children with prenatal hydronephrosis: a prospective study. J Urol. 2015 May;193(5 Suppl):1766-71. DOI: 10.1016/j.juro.2014.10.091
[19] Herz D, Merguerian P, McQuiston L. Continuous antibiotic prophylaxis reduces the risk of febrile UTI in children with asymptomatic antenatal hydronephrosis with either ureteral dilation, high-grade vesicoureteral reflux, or ureterovesical junction obstruction. J Pediatr Urol. 2014 Aug;10(4):650-4. DOI: 10.1016/j.jpurol.2014.06.009
[20] Zareba P, Lorenzo AJ, Braga LH. Risk factors for febrile urinary tract infection in infants with prenatal hydronephrosis: comprehensive single center analysis. J Urol. 2014 May;191(5 Suppl):1614-8. DOI: 10.1016/j.juro.2013.10.035
[21] Song SH, Lee SB, Park YS, Kim KS. Is antibiotic prophylaxis necessary in infants with obstructive hydronephrosis? J Urol. 2007 Mar;177(3):1098-101; discussion 1101. DOI: 10.1016/j.juro.2006.11.002
[22] Gimpel C, Masioniene L, Djakovic N, Schenk JP, Haberkorn U, Tönshoff B, Schaefer F. Complications and long-term outcome of primary obstructive megaureter in childhood. Pediatr Nephrol. 2010 Sep;25(9):1679-86. DOI: 10.1007/s00467-010-1523-0
[23] Braga LH, D'Cruz J, Rickard M, Jegatheeswaran K, Lorenzo AJ. The Fate of Primary Nonrefluxing Megaureter: A Prospective Outcome Analysis of the Rate of Urinary Tract Infections, Surgical Indications and Time to Resolution. J Urol. 2016 Apr;195(4 Pt 2):1300-5. DOI: 10.1016/j.juro.2015.11.049
[24] Wiswell TE, Hachey WE. Urinary tract infections and the uncircumcised state: an update. Clin Pediatr (Phila). 1993 Mar;32(3):130-4. DOI: 10.1177/000992289303200301
[25] Williams N, Kapila L. Complications of circumcision. Br J Surg. 1993 Oct;80(10):1231-6. DOI: 10.1002/bjs.1800801005
[26] Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. Arch Dis Child. 2005 Aug;90(8):853-8. DOI: 10.1136/adc.2004.049353
[27] Bader M, McCarthy L. What is the efficacy of circumcision in boys with complex urinary tract abnormalities? Pediatr Nephrol. 2013 Dec;28(12):2267-72. DOI: 10.1007/s00467-013-2410-2
[28] Mukherjee S, Joshi A, Carroll D, Chandran H, Parashar K, McCarthy L. What is the effect of circumcision on risk of urinary tract infection in boys with posterior urethral valves? J Pediatr Surg. 2009 Feb;44(2):417-21. DOI: 10.1016/j.jpedsurg.2008.10.102
[29] Brandström P, Esbjörner E, Herthelius M, Swerkersson S, Jodal U, Hansson S. The Swedish reflux trial in children: III. Urinary tract infection pattern. J Urol. 2010 Jul;184(1):286-91. DOI: 10.1016/j.juro.2010.01.061

The ZB MED – Information Center for Life Sciences, Germany, together with the European Association of Urology (EAU) provided the opportunity to publish a “Living Textbook” on “Urogenital Infections and Inflammations” in an open access form. This “Living Textbook” represents also an update of the Textbook on Urogenital Infections published 2010 by the International Consultation on Urological Infections and the EAU: http://www.icud.info/urogenitalinfections.html.

The “Living Textbook” will cover infections and inflammations of the kidney, the urinary tract, as well as the male and female genital tract considering pathogenesis, diagnostics, treatment, prophylaxis and future aspects. The “Living Textbook” will be structured into about 26 Sections each with two section co-chairs responsible for peer review of the chapters of each section. Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

The editors hope that this “Living Textbook” may become a useful instrument for physicians of different specialties taking care about patients suffering from these diseases.

Truls E. Bjerklund Johansen (Norway),

Florian ME Wagenlehner (Germany),

Yong-Hyun Cho (South Korea),

Tetsuro Matsumoto (Japan),

John N Krieger (USA),

Daniel Shoskes (USA),

Kurt G. Naber (Germany).

Publishing at PUBLISSO

Your chapter will be published at the PUBLISSO platform (https://books.publisso.de).

Information for corresponding authors

It is necessary for all corresponding authors to register at PUBLISSO.
To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

After registration, please complete your user profile. Information from your user profile will appear in the published chapter and the authors board of the book (http://books.publisso.de/publisso_gold/book/52). If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.
(If you do not want to be displayed in the authors board, but stay registered, you can disable this feature in your profile settings. In this case, your affiliation (publication data) will be displayed in the published chapter only.)

We kindly ask you to provide the co-authors email addresses in the manuscript so that we can contact them in case of queries.

Information for co-authors

After publication of your chapter, your affiliation (publication data) will be displayed in the published chapter.

If you also want to be displayed in the authors board of the book (http://books.publisso.de/publisso_gold/book/52), we kindly ask you to register at PUBLISSO. If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.

To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

If you do not want to be displayed in the authors board of the book, you do not have to register. Your affiliation (publication data) will be displayed in the published chapter only.

Support

If you have any further questions please don’t hesitate to contact the PUBLISSO editorial office:

E-Mail: livingbooks@zbmed.de
Phone: +49 221 478-7093

General

The textbook will be structured in sections with two co-chairs each. Each section will start with an introductory chapter written by the two respective co-chairs presented like an editorial commentary in regard to the following chapters (see proposed contents of the book). The two co-chairs of each section will also peer review all chapters in their section and stimulate a consensus discussion within their section together with the authors and the main editors if needed.

Chapters

Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

Manuscript

Each manuscript should have up to approximately 3,000 words (excluding abstract, tables/figures and references). The abstract should count about 300 words.

Structure

The outline of each chapter should be structured as follows (similar as in the edition 2010, which can be downloaded for free: http://www.icud.info/urogenitalinfections.html):

  1. Abstract
  2. Summary of recommendations*/key notes*
    (*which ever term is more appropriate)
  3. Introduction
  4. Methods
  5. Results
  6. Further research
  7. Conclusions
  8. Acknowledgement
  9. Conflict of interest of each author
  10. References

Citation style

As a citation style, the Vancouver style is preferred.

Please mark your references in the text with square brackets ([1], [2], ...).

Summary of recommendations

We would like to have the Summary of recommendations at the beginning after the abstract (as in the edition 2010). However, we do not expect as in the edition 2010, that each recommendation is also specified according to Level of Evidence and Grade of Recommendation, because such a claim would not only need a systematic literature search (see below), but also a structured discussion in a defined group of experts.

Systematic literature search

A systematic literature search should be performed, at least of PUBMED/MEDLINE but ideally of several relevant databases in addition (like Cochrane CENTRAL) to find recent, high quality systematic reviews and/or primary research studies. It is not expected to perform for all chapters a de novo systematic review, if such reviews are already published recently, but it still may be indicated for some items. For questions relating therapy, it should be focused on evidence from (systematic reviews of) randomized controlled trials if available.

The method of the systematic literature search needs to be fully described in the section “Methods”, e.g.:

“A systematic literature search was performed for the last ... (usually 10) years in MEDLINE, Cochrane etc. with the following key words ... and the following limitations: e.g. UTI, age (adult?), ... clinical studies ... English ... abstract available ... only peer reviewed ...

A total of ... publications were identified, which were screened by title and abstract ... After exclusion of duplicates ... a total of ... were included into the review (analysis), supplemented by citations or known to the authors ... ”.

Clinical topics

Clinical topics should be focused on the importance to clinical practice according to the up to date scientific knowledge as presented in the literature. It should relate to questions/complaints/symptoms of patient/population concerning definition, diagnosis, therapy/prevention, intervention, and outcome in comparison, if different approaches are feasible. Please choose patient-important outcomes and focus on those, which you deem critical for decision-making.

Level of evidence and grade of recommendations

Any recommendation should be based on the level of evidence and the grade of recommendation. For this purpose the following system, modified from the Oxford Centre for Evidence-based Medicine should be used (EAU guidelines 2015):

Level of evidence (LE)

Level Type of evidence
1a Evidence obtained from meta-analysis of randomised trials
1b Evidence obtained from at least one randomised trial
2a Evidence obtained from one well-designed controlled study without randomization
2b Evidence obtained from at least one other type of well-designed quasi-experimental study
3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports.
4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities.

Grade of Recommendations (GoR)

Grade Nature of recommendations
A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial
B Based on well-conducted clinical studies, but without randomised clinical trials
C Made despite the absence of directly applicable clinical studies of good quality

Comments (EAU guidelines 2015)

The aim of assigning a LE and grading recommendations is to provide transparency between the underlying evidence and the recommendation given.

It should be noted that when recommendations are graded, the link between the level of evidence and grade of recommendation is not directly linear. Availability of randomized controlled trials may not necessarily translate into a grade “A” recommendation where there are methodological limitations or disparity in published results.

Alternatively, absence of high level evidence does not necessarily preclude a grade A recommendation, if there is overwhelming clinical experience and consensus. In addition, there may be exceptional situations where corroborating studies cannot be performed, perhaps for ethical or other reasons and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor – has to be balanced against benefits and burdens, values and preferences and costs when a grade is assigned.

Since the same rating system should be used in all chapters, for the sake of brevity the same sentence could be used in “Methods” for all manuscripts, because the rating system will be described in details in the Preface of the book:

“The studies were rated according to the level of evidence and the strength of recommendations graded according to a system used in the EAU guidelines modified from the Oxford Centre for Evidence-based Medicine [1].”

References

[1] European Association of Urology. Guidelines. Methodology section. 2015 ed. Arnhem: European Association of Urology; 2015. p. 3. ISBN/EAN: 978-90-79754-80-9. Available from: http://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn..pdf

The Living Handbook of Urogenital Infections and Inflammations is issued by:

European Association of Urology
att. Maurice Schlief, EAU executive manager business affairs

P.O.Box 30016
NL-6803 AA Arnhem, The Netherlands

Phone: 0031-26-38.90.680
E-mail: m.schlief@uroweb.org

Editor in Chief

responsible for the contents according to § 5 TMG and § 55 Abs. 2 RStV (Germany):

Kurt G. Naber, MD, PhD
Assoc. Professor of Urology

Technical University of Munich
Karl-Bickleder-Str. 44c
94315 Straubing, Germany

E-mail: kurt.naber@nabers.de

John N. Krieger MD, PhD

University of Washington Section of Urology

more

Daniel Shoskes MD, PhD

Cleveland Clinic Glickman Urological and Kidney Institute

more

Yong-Hyun Cho MD, PhD

St. Mary's Hospital, The Catholic University of Korea Department of Urology

more

Tetsuro Matsumoto MD, PhD

University of Occupational and Environmental Health Department of Urology

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen Clinic of Urology and Andrology

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital Urology Department

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Punit Bansal MD, PhD

R G Stone and Super Specialty Hospital
Department of Urology

more

Riccardo Bartoletti

University of Pisa
Department of Translational Research and New Technologies

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital
Urology Department

more

PD Dr. med. Gernot Bonkat

University Basel
alta uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB)

more

Prof. Tommaso Cai MD

Santa Chiara Regional Hospital
Dept. of Urology

more

Dr Leyland Chuang

Ng Teng Fong Hospital, National University Health System
Department of Medicine

more

Prof. Milan Cizman

University Medical Centre
Department of Infectious Diseases

more

Alison Crawford MSc

Queen's University
Department of Psychology

more

Pfofessor Svetlana Dubrovina MD, PhD

Rostov Medical State University
Obstetrics and Gynaecology

more

Dr Valerie Huei Li Gan MBBS (S'pore), MRCS (Edin), MMed (Surg), FAMS (Urology)

Singapore General Hospital
Department of Urology

more

Philip Hanno

University of Pennsylvania

more

Ass prof MD Gundela Holmdahl

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Udo B. Hoyme

HELIOS Hospital Erfurt Ltd.
Department of Gynecology and Obstetrics

more

David Hunstad

Washington University School of Medicine
Pediatrics / Molecular Microbiology

more

Gitte M. Hvistendahl

Aarhus University Hospital

more

Prof. Michael KOGAN M.D., PhD

Rostov State Medical University
Department of Urology

more

Dr Akihiro Kanematsu

Hyogo College of Medicine
Department of Urology

more

Frieder Keller

University Hospital Ulm
Department Internal Medicine 1, Nephrology

more

Professor Katarzyna Kilis-Pstrusinska PhD, MD

Wroclaw Medical University
Department of Pediatric Nephrology

more

MD, PhD Tae-Hyoung Kim

Chung-Ang University
Urology

more

John N. Krieger MD, PhD

University of Washington
Section of Urology

more

Prof Ekaterina Kulchavenya

Novosibirsk Research TB Institute, Novosibirsk State Medical University

more

Dr Christina Kåbjörn Gustafsson

Ryhov Hospital Jönköping
Pathology

more

Dr. Bela Köves

South Pest Teaching Hospital
Department of Urology

more

Iara Linhares

Dr. med. Giuseppe Magistro

Ludwig-Maximilians-University of Munich
Department of Urology

more

Vittorio Magri

ASST-North
Urologic Clinic

more

András Magyar

South-Pest Hospital
Department of Urology

more

Professor Emeritus Brian Morris

University of Sydney
School of Medical Sciences

more

Baerbel Muendner-Hensen

ICA-Deutschland e.V.

more

Stephen F. Murphy

Feinberg School of Medicine, Northwestern University
Department of Urology

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Prof. Yulia Naboka

Rostov State Medical University
Department of Microbiology

more

Dr. J. Curtis Nickel MD

Queen's University
Department of Urology

more

Professor Ralph Peeker MD PhD

University of Gothenburg
Department of Urology

more

Tamara Perepanova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology

more

Prof. Gianpaolo Perletti M. Clin. Pharmacol.

University of Insubria
Department of Biotechnology and Life Sciences

more

Felice Petraglia

Department of Biomedical, Experimental and Clinical Sciences, University of Florence
Obstetrics and Gynecology

more

Michel Pontari

Temple University School of Medicine
Department of Urology

more

Dr. Jörgen Quaghebeur PhD. Med. Sci.

University Hospital Antwerp and University Antwerp
Department of Urology

more

Yazan F. Rawashdeh

Aarhus University Hospital
Paediatric Urology Section, Department of Urology

more

Professor Claus Riedl MD

-
Urology

more

Matthew Roberts

The University of Queensland
Faculty of Medicine

more

PD Dr. med Guido Schmiemann MPH

Institut für Public Health und Pflegeforschung, Universität Bremen
Abteilung Versorgungsforschung

more

Caroline Schneeberger MD PhD

Academic Medical Center (AMC)

more

Prof. Dr. med. Peter Schneede

Klinikum Memmingen
Department of Urology

more

Aaron C. Shoskes

Des Moines University Medical College of Ostheopathic Medicine

more

Daniel Shoskes MD, PhD

Cleveland Clinic
Glickman Urological and Kidney Institute

more

Prof. Dr. Roswitha Siener

University of Bonn
University Stone Centre, Department of Urology

more

Sofia Sjöström

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Mathew Sorensen

University of Washington School of Medicine
Department of Urology

more

Prof. Dr. Dr. Walter Ludwig Strohmaier FEBU

Regiomed-Klinikum Coburg. Medical School Regiomed
Urology and Paediatric Urology

more

Satoshi Takahashi

Sapporo Medical University School of Medicine
Department of Infection Control and Laboratory Medicine

more

Professor Paul Anantharajah Tambyah

Yong Loo Lin School of Medicine, National University Hospital
Department of Medicine

more

Peter Tenke

Jahn Ferenc South Pest Teaching Hospital
Department of Urology

more

Praveen Thumbikat


Department of Urology

more

Dr. Jose Tiran Saucedo

IMIGO / Universidad de Monterrey
Obstetrics and Gynaecology

more

Dominic Tran-Nguyen

Des Moines University

more

Dean Tripp

Queen's University
Psychology, Anesthesia & Urology

more

Prof. SEONGHEON WIE

The Catholic University of Korea, St. Vincent's Hospital
Division of Infectious Diseases, Department of Internal Medicine

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen
Clinic of Urology and Andrology

more

Assoc. Prof. Christian Wejse

Aarhus University, Aarhus University Hospital
Department of Infectious Diseases/Center for Global Health, Dept of Public Health

more

Prof. Dr. Mete Çek

Trakya University, School of Medicine
Urology

more